X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AMAR REMEDIES LIMITED Quarterly Results - Equitymaster
 
AMAR REMEDIES LIMITED  - Last 8 Quarters  (AMAD)

Here are the latest quarterly results of AMAR REMEDIES. For more details, see the AMAR REMEDIES financial fact sheet and AMAR REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.
 Interim Results
No. of Months
Qtr. Ending
3
Sep-11
3
Dec-11
3
Mar-12
3
Jun-12
3
Sep-12
3
Dec-12
3
Mar-13
3
Jun-13
8-Qtr Chart
Click to enlarge
Net Sales Rs m1,5911,6491,6931,8111,5241,6301,310452 
Other income Rs m014525420 
Turnover Rs m1,5911,6631,6981,8131,5291,6341,312452 
Expenses Rs m1,3591,4051,4131,4371,3631,4471,219531 
Gross profit Rs m23224427937316018391-80 
Depreciation Rs m2828284331474721 
Interest Rs m8890104116119124139146 
Profit before tax Rs m1161401522161516-93-247 
Tax Rs m181823643300 
Profit after tax Rs m981221291521213-93-247 
Gross profit margin %14.614.816.520.610.511.26.9-17.7 
Effective tax rate %15.512.915.129.620.018.80.00.0 
Net profit margin %6.27.47.68.40.80.8-7.1-54.6 
Diluted EPS Rs 3.7 4.7 4.9 5.8 0.5 0.5 -3.6 -9.4  
Diluted EPS (TTM) Rs 15.0 16.1 17.3 19.2 15.9 11.7 3.2 -12.0  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster



Today's Market

Sensex Closes up 172 Points; Axis Bank Soars 3.3%(Closing)

Indian share markets continued to witness buying momentum in the afternoon session. At the closing bell, the BSE Sensex stood higher by 172 points, while the NSE Nifty finished up by 56 points.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

Doubled Your Money In D-Mart? Read This Before It's Too Late(Daily Profit Hunter)

Mar 22, 2017

Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

Why Mutual Fund Investors Should Not Worry About Market High. But...(Outside View)

Mar 22, 2017

PersonalFN provides a prudent investment strategy to invest in mutual funds as market scales a new high.

More

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AMAR REMEDIES

AMAR REMEDIES 5-YR ANALYSIS

Detailed Financial Information With Charts

COMPARE AMAR REMEDIES WITH

MARKET STATS